Professor of Clinical Oncology, University of Glasgow
Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with targeted drug therapies, but his research interests in radiotherapy-drug combinations extend across tumour sites including lung cancer and mesothelioma. He is Chief Investigator for a portfolio of early phase clinical trials evaluating the oral PARP inhibitor olaparib in combination with radiotherapy and/or chemotherapy in treatment of glioblastoma, and also leads the randomised phase II SYSTEMS-2 trial of radiotherapy dose escalation in mesothelioma. He is Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and is a scientific theme lead for the Radiotherapy-Drug Combinations Consortium (RaDCom), a joint initiative between Cancer Research UK and the UK National Cancer Research Institute. He sits on the Scientific Committees of the European Association for Neuro-Oncology (EANO) and the European Society for Therapeutic Radiation Oncology (ESTRO), and is Chair of the Scottish Radiotherapy Research Forum (ScoRRF).